日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Adoption of Decentralized Trial Elements in Cancer Clinical Trials Supporting FDA Approvals during COVID-19

新冠疫情期间，癌症临床试验中采用分散式试验要素支持FDA批准

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-24-3357
Patel, Timil H; Corneli, Amy; Balcazar, Pamela; Lipset, Craig; Calvert, Sara B; Mervin-Blake, Sabrena; Nalawade, Vinit; Kluetz, Paul G
微生物学
新冠
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma

FDA批准摘要：Tremelimumab联合Durvalumab用于治疗不可切除的肝细胞癌患者

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-23-2124
Patel, Timil H; Brewer, Jamie R; Fan, Jiaxin; Cheng, Joyce; Shen, Yuan-Li; Xiang, Yue; Zhao, Hong; Lemery, Steven J; Pazdur, Richard; Kluetz, Paul G; Fashoyin-Aje, Lola A
细胞生物学
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement

FDA批准摘要：Pemigatinib用于治疗既往接受过治疗、无法切除的局部晚期或转移性胆管癌，伴有FGFR2融合或其他重排

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-22-2036
Patel, Timil H; Marcus, Leigh; Horiba, M Naomi; Donoghue, Martha; Chatterjee, Somak; Mishra-Kalyani, Pallavi S; Schuck, Robert N; Li, Yangbing; Zhang, Xinyuan; Fourie Zirkelbach, Jeanne; Charlab, Rosane; Liu, Jiang; Yang, Yuching; Lemery, Steven J; Pazdur, Richard; Theoret, Marc R; Fashoyin-Aje, Lola A
肿瘤
胆管癌
FGFR2
肿瘤免疫
发表日期：2023
文献求助 收藏

The emergence of surgeon-controlled robotic surgery in urologic oncology

泌尿肿瘤外科领域外科医生控制的机器人手术的出现

期刊:Indian Journal of Surgical Oncology
影响因子:0.7
doi:10.1007/s13193-011-0105-3
Patel, Timil H; Babbar, Paurush; Hemal, Ashok K
肿瘤
肿瘤免疫
发表日期：2012
文献求助 收藏